This story originally ran on Aug. 16.
Vermillion this week reported $321,000 in revenues for the second quarter of 2012, up 6 percent from $304,000 in same period last year.
The rise was driven by an increase in sales of the company's OVA1 ovarian cancer diagnostic. Test volume for OVA1 was 4,150 during the quarter, up 6 percent compared to Q2 2011 and in line with the company's forecast.
Vermillion's license revenues, collected through its agreement with Quest Diagnostics, were flat year over year at $113,000.